A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), although the company says there are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results